Tuesday's lunch break presents the usual mid-week theater of distraction.
First, $SKIN spikes 41% after an FDA clearance for treating periorbital wrinkles. A real healthcare milestone. Too bad history shows that chasing a 30% gap-up on a medical device catalyst closes red 65% of the time across similar setups.
Then we have $BJDX, a $1M micro-cap gapping up 28% on zero news. Retail is piling in blind, hoping to catch a legendary low-float squeeze. Out of 3,671 historical instances of low-float gap-ups on zero news, the median intraday return is -8.17%, with 68% closing red.
If you are buying the $BJDX mystery pump to pay for your $SKIN wrinkle treatment, you are paying the ultimate lack-of-discipline premium. Close the laptop and go eat your sandwich.